



Morton's neuroma: A systematic review of pathophysiology, diagnosis, and management

Nerwiak Mortona: przegląd patofizjologii, diagnostyki i leczenia

Magdalena Zielińska¹ , Jan Kucharski² , Michał Kotowicz¹ , Joanna Ciećwierz¹ , Aleksandra Zagórska¹ ,
Paweł Szajewski¹ , Maria Koczkodaj³ , Magdalena Bieniak² , Patrycja Łazicka⁴

¹Szpital Wolski im. dr Anny Gostyńskiej Sp. z o.o., Warszawa, Polska /
Dr. Anna Gostyńska Wolski Hospital, Warsaw, Poland

²Szpital Praski p.w. Przemienienia Pańskiego Sp. z o.o., Warszawa, Polska /
Praski Hospital of the Transfiguration of Our Lord, Warsaw, Poland

³Warszawski Szpital Południowy Sp. z o.o., Polska / Warsaw Southern Hospital, Warsaw, Poland

⁴Central Clinical Hospital of the University Clinical Center of the Medical University of Warsaw, Poland

ABSTRACT

Morton's neuroma (MN) is a common neuropathy of the interdigital nerve, most often between the third and fourth metatarsal heads. Despite its common occurrence, approaches to diagnosis and treatment may differ. This review summarizes current evidence on the pathophysiology, diagnostic evaluation, and management of MN. We conducted a PubMed search for randomized controlled trials, cohort studies, and systematic reviews published up to October 2025, using the terms "Morton's neuroma," "interdigital neuralgia," "forefoot pain," and "nerve entrapment," with a focus on clinical presentation, imaging, and treatment. Case reports, letters, non-English-language articles, and conference abstracts were excluded. MN typically affects middle-aged women and is commonly related to mechanical compression, footwear, and foot biomechanics. Diagnosis is mainly clinical, with provocative tests such as Mulder's click helping to identify the condition. Ultrasound is a first-line imaging tool, due to its high diagnostic accuracy and capacity for real-time guidance. Non-surgical therapies, such as different footwear, orthoses, and ultrasound-guided corticosteroid injections, can provide short-term improvement in symptoms, usually lasting up to 12 months. Approximately one third of patients may require surgery. Surgical options, such as neurectomy, intermetatarsal ligament release, and dorsal nerve transposition, can provide long-term relief, but they carry risks of sensory loss, stump neuroma, and recurrence. Emerging minimally invasive techniques show potential, but need further study. Management should be tailored to the severity of symptoms and their impact on functioning in order to achieve the best outcomes.

KEYWORDS

compressive neuropathy, dorsal nerve transposition, forefoot pain, interdigital neuralgia, interdigital neurectomy, Morton's neuroma, ultrasound-guided corticosteroid injections

Received: 13.11.2025 Revised: 11.01.2026 Accepted: 18.01.2026 Post-print published: 30.04.2026 Final published: 09.10.2026

Address for correspondence: dr Magdalena Zielińska, Szpital Wolski im. dr Anny Gostyńskiej Sp. z o.o., ul. Marcina Kasprzaka 17, 01-211 Warszawa, tel. +48 22 389 47 00, e-mail: magda.zielinska20@gmail.com



This is an open access article made available under the terms of the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license, which defines the rules for its use. It is allowed to copy, alter, distribute and present the work for any purpose, even commercially, provided that appropriate credit is given to the author and that the user indicates whether the publication has been modified, and when processing or creating based on the work, you must share your work under the same license as the original. The full terms of this license are available at <https://creativecommons.org/licenses/by-sa/4.0/legalcode>.

© Copyright by Author(s)

Publisher: Medical University of Silesia, Katowice, Poland



STRESZCZENIE

Nerwiak Mortona (*Morton's neuroma* – MN) to częsta neuropatia nerwu podeszwowego palcowego wspólnego, występująca najczęściej między trzecią i czwartą kością śródstopia. Mimo powszechnego występowania schorzenia metody diagnostyki i leczenia mogą się różnić. Celem niniejszego przeglądu jest podsumowanie aktualnej wiedzy dotyczącej patofizjologii, diagnostyki i leczenia MN. Przeszukano bazę PubMed, uwzględniając randomizowane badania kliniczne, badania kohortowe oraz przeglądy systematyczne opublikowane do października 2025 r., z użyciem terminów: „nerwiak Mortona”, „neuralgia międzypalcowa”, „ból przodostopia” i „ucisk nerwu”, ze szczególnym uwzględnieniem obrazu klinicznego, badań obrazowych i metod leczenia. Wykluczono opisy przypadków, listy, publikacje nieanglojęzyczne oraz streszczenia konferencyjne. MN najczęściej dotyczy kobiet w średnim wieku i wiąże się z przewlekłym obciążeniem przodostopia, typem noszonego obuwia oraz biomechaniką stopy. Rozpoznanie opiera się głównie na obrazie klinicznym. Najbardziej pomocne są testy prowokacyjne, w tym test Muldera, oraz tkliwość w okolicy przestrzeni międzypalcowej. Ultrasonografia jest metodą obrazowania pierwszego wyboru ze względu na wysoką czułość i możliwość jednoczesnego przeprowadzania testów diagnostycznych. Rezonans magnetyczny zaleca się w przypadkach niejednoznacznych. Leczenie zachowawcze – zmiana obuwia, stosowanie ortez oraz iniekcje kortykosteroidów pod kontrolą ultrasonografii – może przynieść krótkotrwałą poprawę, utrzymującą się zazwyczaj do 12 miesięcy. Szacuje się, że około jednej trzeciej pacjentów wymaga leczenia operacyjnego. Metody chirurgiczne, takie jak neurektomia, przecięcie więzadła międzysródstopnego lub transpozycja nerwu, zapewniają długoterminową poprawę, ale mogą prowadzić do utraty czucia, powstania nerwiaka kikuta lub nawrotu dolegliwości. Metody minimalnie inwazyjne, takie jak ablacja prądem o częstotliwości radiowej czy krioablacja, są obiecujące, lecz wymagają dalszych badań. Optymalne wyniki uzyskuje się dzięki indywidualizacji leczenia.

SŁOWA KLUCZOWE

neuropatia uciskowa, transpozycja nerwu grzbietowego stopy, ból przodostopia, neuralgia międzypalcowa, neurektomia nerwu międzypalcowego, nerwiak Mortona, iniekcje kortykosteroidów pod kontrolą ultrasonografii

INTRODUCTION

Morton's neuroma (MN) is a compressive neuropathy affecting the common plantar digital nerve. Its most frequent location is between the third and fourth metatarsal heads. The condition develops from chronic irritation and mechanical entrapment of the interdigital nerve beneath the deep transverse intermetatarsal ligament. This results in progressive neural degeneration. Histological findings typically reveal endoneurial edema, axonal degeneration with segmental demyelination, arterial degeneration, and dense perineural fibrosis – all of which may present as localized forefoot pain and altered sensation [1,2,3,4,5,6,7].

Epidemiological data show that MN mainly affects middle-aged women and women in general are five times more likely to develop the condition than men [8]. This difference is attributed to biomechanical differences and external factors, especially the use of narrow or high-heeled shoes, which increases plantar pressure across the metatarsal heads [8]. Although there is no precise data about the incidence of MN in the general population, it is among the most common causes of forefoot pain encountered in orthopedic and primary care practice [8]. Population data from the United Kingdom estimates approximately 87.5 cases per 100,000 women and 50.2 per 100,000 men per year [9], making MN the third most common condition referred to foot and ankle surgeons in the UK [10]. Neuromas can be present in all four intermetatarsal spaces. However, the third interspace is by far the most

frequently affected, from 42% to 86%, followed by the second interspace, ranging from 5% to 57% [11,12]. MN typically presents unilaterally, though multiple neuromas developing within the same foot are relatively common, often located in adjacent intermetatarsal spaces. Bilateral cases are uncommon [13]. Radiological studies have shown that subclinical or asymptomatic neuromas may coexist within the same foot, suggesting that the actual prevalence of MN is likely underreported [8,13].

METHODS

This review was conducted by searching the PubMed database for papers on MN. The search criteria were a date of publication up to October 2025, the search terms “Morton's neuroma,” “interdigital neuroma,” “forefoot pain,” and “nerve entrapment,” and a focus on pathophysiology, imaging, epidemiology, clinical presentation, and management of MN. Both original research and review papers were considered, whereas non-English-language articles and conference abstracts were excluded.

REVIEW

Clinical presentation

MN typically presents with localized forefoot pain. That pain is often described by patients as a burning or stabbing feeling that spreads into the toes, most often



on either side of the involved interspace [2,14]. The pain commonly appears during longer walks or when wearing tight shoes. Removing footwear or massaging the area usually brings quick relief [2,14]. Many patients describe a sensation of “walking on a pebble” or feeling fullness beneath the metatarsal heads. While this sensation is not unique to MN, it tends to prompt closer examination of the affected area [2,15,16]. Other symptoms include sensory changes, such as numbness, tingling, or paresthesia in the nearby toes, which is the result of compression and irritation of the interdigital nerve. As the condition advances, pain can become severe, significantly limiting walking and physical activity [2,14].

Diagnosis

Findings of physical examination

Physical examination remains crucial to the diagnostic evaluation of MN. Palpation of the intermetatarsal spaces often reveals localized tenderness. Among provocative maneuvers, Mulder's test is particularly informative. It is performed by compressing the metatarsal heads while palpating the interspace, which produces a palpable or audible “click” and a sharp pain radiating to the toes. This sign is considered highly specific (specificity ≈ 0.96 ; $LR^+ \approx 13.1$) and a positive result strongly supports the diagnosis [14,15]. Webspace tenderness test (thumb–index finger squeeze test) has shown high sensitivity (≈ 0.96 ; $LR^- \approx 0.04$), making it useful to rule out MN when negative [14,15].

Other frequently reported symptoms include burning forefoot pain (sensitivity: 54%–57%; specificity: 48%) and the “pebble” sensation (sensitivity: 43%–53%; specificity: 52%) [14,15,16]. Although none of these findings are conclusive on their own, the combination of pain pattern, site-specific tenderness, and positive provocative tests significantly increases diagnostic confidence [14].

Primary care physicians need to recognize that MN often coexists with other forefoot conditions, such as metatarsalgia, bursitis, or plantar plate injuries, which can complicate diagnosis and treatment. Clinicians should be especially alert with women aged 40–60 years who present with chronic plantar forefoot pain that does not respond to footwear modifications or orthotic use. Early detection enables non-surgical management and may help prevent chronic nerve damage.

Table I presents the diagnostic accuracy of subjective features and physical examination tests in patients with MN. Pitcher et al. [14] analyzed the diagnostic value of subjective features using likelihood ratios (LR). Patient-reported clicking was the strongest indicator, with an LR^+ of 13.14, providing strong evidence for MN. Other symptoms, including burning pain and “walking on a pebble,” had LR^+ values below 2, offering limited diagnostic utility. Features such as pain in the second or third interspace, paresthesia, clicking, and pain from tight shoes showed an LR^- between 0.2 and 0.5, giving modest evidence against MN when absent, while all other features had an LR^- above 0.5, indicating low value for ruling out the condition.

Table I. Diagnostic accuracy of subjective features and physical examination tests for Morton's neuroma

Symptom / Test	Sensitivity	Specificity	Positive LR	Negative LR
Subjective clicking (patient-reported)	–	0.96	13.14	–
Modified webspace tenderness (thumb–index squeeze test)	0.96	0.49	1.88	0.04
Mulder's click (palpable/audible)	0.61–0.94	0.62–0.97	2.1–12.0	0.09–0.63
Burning forefoot pain	0.54–0.57	0.48	1.04	0.92
Sensation of “walking on a pebble”	0.43–0.53	0.52	0.9–1.1	0.88
Pain aggravated by walking	0.91–0.92	0.37–0.55	1.45	0.16
Pain aggravated by footwear	0.75–0.86	0.42–0.60	1.4	0.25
Forefoot pain (any)	1.00	0.13	1.15	0.00
Dysesthesia / Altered sensation	0.00	0.70–0.80	–	–

Note: The data are from Pitcher et al. [14] and have been reformatted and paraphrased for clarity, though all values are presented as reported in the original systematic review. LR – likelihood ratios.

Radiological diagnosis

Imaging plays a crucial role in confirming the diagnosis of Morton's neuroma and distinguishing it from other causes of metatarsalgia. Radiological evaluation can help confirm the diagnosis, define the lesion's size and position, and provide valuable preoperative information. Ultrasound (US) and magnetic resonance

imaging (MRI) are considered the most reliable and informative techniques [17,18,19].

Plain radiographs are typically not relevant in MN. In some cases, a slight widening of the intermetatarsal space or a splaying of adjacent toes (Sullivan's sign) may suggest a soft-tissue lesion, though these findings are nonspecific and not diagnostic [1,20]. US is the preferred imaging modality [11,21,22] due to its



availability, low cost, absence of contraindications, and ability to correlate with pain in real time [7]. On US, MN typically appears as a well-defined, hypoechoic, round or ovoid lesion within the intermetatarsal space, just proximal to the metatarsal heads. The lesion is usually noncompressible and, in some cases, may demonstrate heterogeneous echotexture due to variable fibrosis and edema [7,19,20]. The examination can be performed from either a dorsal or plantar approach, though the dorsal sagittal view is often easier and more comfortable for the patient [23]. Each intermetatarsal space is systematically assessed and gentle probe pressure may reproduce characteristic pain. Applying pressure with the probe may reproduce the patient's characteristic pain, known as the sonographic Mulder's sign, which supports the clinical diagnosis [1,17,24]. MRI findings typically show a spindle- or dumbbell-

-shaped soft-tissue mass located in the intermetatarsal space. Such lesions demonstrate low to intermediate signal intensity on T1-weighted images, low signal on T2-weighted sequences, and variable enhancement following gadolinium administration. MRI is particularly useful for evaluating surrounding soft-tissue structures and distinguishing MN from other causes of forefoot pain, such as intermetatarsal bursitis, plantar plate injury, or capsular inflammation [25,26]. Table II presents a comparison of different radiological techniques in the diagnosis of MN.

Lesion size is an important radiological clue: symptomatic neuromas tend to measure over 5 mm in diameter, whereas smaller ones are often incidental or asymptomatic findings [25]. Integrating imaging data with clinical features remains crucial for accurate diagnosis and individualized management.

Table II. Comparison of different radiological techniques in the diagnosis of Morton's neuroma (MN) [1]

Imaging modality	Typical findings	Diagnostic performance	Clinical advantages	Limitations
Plain radiography	Usually normal; may show widening of intermetatarsal space or divergence of adjacent toes (Sullivan's sign)	Non-specific; cannot directly visualize the lesion	Excludes fractures, deformities, or degenerative changes that mimic MN	Very low sensitivity and specificity for MN; not diagnostic
Ultrasound	Ovoid or fusiform hypoechoic lesion within intermetatarsal space, contiguous with plantar digital nerve; may elicit a sonographic Mulder's sign	Sensitivity 85%–95%; specificity 80%–90% [17,18]	Inexpensive, widely available, dynamic correlation with pain, option for image-guided injection in the same session	Operator-dependent; may overestimate lesion size when a bursal component is present
Magnetic resonance imaging	Ovoid or dumbbell-shaped lesion located plantar to the deep transverse metatarsal ligament; low-to-intermediate signal on T1 and T2; variable enhancement post-contrast	Sensitivity 82%–90%; specificity 88%–90% [17,18]	Excellent soft-tissue contrast; useful for equivocal or complex cases and pre-surgical mapping	High cost, limited availability; lesions may be inconspicuous on fat-suppressed sequences

Clinical assessment protocol

A clearer diagnosis can be made with the assistance of the clinical assessment protocol (Delphi recommendations) for diagnosing forefoot neuroma presented in a study by Dando et al. [15]. The protocol consists of 21 recommendations divided into following themes: location of pain, non-weight-bearing sensation,

weight-bearing sensation, observations, and tests and imaging [15].

Treatment

Table III presents a practical summary of the diagnosis and management pathway for patients diagnosed with Morton's neuroma.

**Table III.** Diagnosis and management pathway for patients diagnosed with Morton's neuroma

Step 1: Clinical assessment
• Evaluate forefoot pain and perform Mulder's squeeze test • Identify symptoms typical of MN (burning pain, tingling between toes, or relief after removing shoes)
Step 2: Imaging
• First-line: US for diagnosis and dynamic assessment • Second-line: MRI if US is inconclusive or to assess differential diagnoses (bursitis or plantar plate tear)
Step 3: Conservative management
• Modify footwear (wide toe box and low heel) • Use metatarsal pads or custom orthoses • Consider pharmacologic pain management or physiotherapy
Step 4: Minimally invasive options
• US-guided corticosteroid or alcohol injection (possible temporary relief) • Consider radiofrequency ablation, cryoablation, or extracorporeal shockwave therapy if conservative care fails
Step 5: Surgical intervention
• Reserved for persistent cases (>6–12 months) • Choose between neurectomy, decompression (DTIML release), or nerve transposition, depending on neuroma size and chronicity • Postoperative follow-up for recurrence or sensory disturbance

MN – Morton's neuroma; US – ultrasound; MRI – magnetic resonance imaging; DTIML – deep transverse intermetatarsal ligament

Non-surgical treatment

First-line treatment begins with conservative measures (shoe modification, orthoses, or activity modification) and may progress to image-guided injections if symptoms persist. A systematic review of non-surgical therapies concluded that corticosteroid injections produce statistically significant short-term pain reduction and about a 50% success rate at 12 months in pooled series [27,28,29,30,31], while other methods – including alcohol injections [32,33,34,35,36,37,38], radiofrequency ablation [39,40], cryoablation [41], extracorporeal shock wave therapy [42,43], capsaicin [44], botulinum toxin [45], orthoses [46], and YAG laser therapy [47] – show variable but sometimes clinically meaningful benefits; however, the quality and comparability of studies are limited and larger randomized trials are needed [48].

Corticosteroid injections

Corticosteroid (CS) injection, often combined with a local anesthetic (LA) (CS + LA), remains one of the most commonly used nonsurgical options for MN. Evidence from a recent Cochrane review indicates that CS + LA provides little or no difference in pain or functional outcomes compared with LA alone at 3–6 months [49]. Adverse effects are rare and usually mild, such as temporary skin atrophy or plantar fat-pad thinning [49].

A systematic review of 5 studies (3 randomized clinical trials, 1 comparative study, and 1 cohort study) found that CS injections led to a modest reduction in pain scores, from a mean Visual Analogue Scale (VAS)

score of 6.6 to 4.3, after approximately 11 months of follow-up [27,28,29,48]. Symptomatic improvement and functional gains were generally greater in neuromas smaller than 5 mm on US [31]. Sustained improvement for up to 12 months has been observed in most studies. Still, approximately half of patients experience a recurrence of symptoms beyond one year, and around one third ultimately undergo surgical excision for persistent pain [48]. Adverse effects such as mild skin atrophy or hypopigmentation are uncommon.

Randomized trials report better outcomes at 6 months when CS injections are performed under US guidance rather than blindly. Additionally, they report clinically significant additional pain reduction (≈ -15 mm on a 0–100 VAS), improved functional scores (standardized mean difference [SMD] ≈ -0.47), and higher patient satisfaction (risk ratio [RR] ≈ 1.7) with no clear increase in adverse events [31,50]. This supports the use of US for targeting corticosteroid injections.

Overall, corticosteroid therapy offers a safe, moderately effective option for short-term management, particularly in small lesions, but long-term durability remains limited, highlighting the need for extended follow-up [48].

Surgical treatment

Surgery is typically reserved for patients with persistent symptoms despite adequate conservative therapy. The standard procedure – interdigital neurectomy – provides reliable pain relief for many patients, but is associated with a considerable risk of permanent digital



numbness, stump neuroma formation, and residual neuropathic pain. As a result, nerve-preserving or decompressive techniques have gained attention as potential alternatives [51].

Isolated release of the deep transverse intermetatarsal ligament (DTIML) has shown promising results in small clinical series. In one study of 12 patients followed for a mean of 13.5 months, VAS pain scores decreased from 6.4 to 2.0, with no reported cases of stump neuroma or permanent numbness [52].

Neurolysis and decompression of the interdigital nerve through a dorsal approach (Dellon technique) have demonstrated significant improvements in pain and function, with low complication rates and preservation of cutaneous sensation in most patients, supporting this as a technically simple, nerve-sparing option [53].

Dorsal nerve transposition or dorsal neurolysis – relocating the nerve to a tension-free position – has been associated with favorable long-term outcomes. In a large retrospective series, 64% of patients reported complete pain relief, though sensory deficits occurred in approximately two thirds of cases and 19% expressed postoperative regret, underscoring the balance between pain reduction and sensory loss [54].

A systematic review comparing operative techniques other than neurectomy found lower rates of postoperative neurogenic symptoms following neurolysis than after nerve excision. The review suggested that combining neurolysis with dorsal transposition may optimize outcomes while minimizing complications. However, the quality of evidence remains variable, and minimally invasive procedures such as percutaneous DTIML release show inconclusive long-term efficacy. When neurectomy is performed, burying or transposing the nerve stump is recommended to reduce the risk of recurrent neuroma formation [51].

Outcomes and recurrence

Surgical management of MN provides substantial relief of symptoms in most patients, with reported success rates of 70%–85%. However, 15%–30% experience persistent or recurrent pain due to stump neuroma, scar

entrapment, or incomplete excision and up to 20% may require revision surgery [52,53].

Dorsal surgical approaches are typically linked to faster recovery and fewer wound complications, while plantar access may reduce recurrence risk in select patients [53]. Nerve-sparing methods, including decompression and dorsal transposition, have shown durable pain relief with lower neurogenic complication rates: in one long-term series, 64% of patients reported complete pain resolution, although sensory loss remained common [54].

The risk of recurrence increases with larger neuromas, longer symptom duration, or prior interventions. Techniques embedding or transposing the nerve stump may help reduce painful recurrence [51].

Overall, surgery remains effective for refractory cases, but patients should be counselled about possible sensory loss and recurrence.

CONCLUSIONS

MN remains a frequent cause of forefoot pain and its evaluation relies mainly on a thoughtful clinical assessment. Diagnosis should rely on careful clinical assessment supported by US imaging, which improves both accuracy in diagnosis and the precision of treatment. Conservative management, including changing footwear, orthoses, and US-guided corticosteroid injections, should be prioritized as first-line therapies. Surgical or minimally invasive interventions, such as neurectomy, decompression, or radiofrequency ablation, are reserved for cases unresponsive to non-surgical care. A stepwise, evidence-based approach and further high-quality studies are needed to optimize long-term outcomes and guide standardized management for patients with MN.

Use of AI tools statement

Grammarly was used solely for language editing to improve clarity and fluency; it did not influence the scientific content of the manuscript.

Authors' contribution

Study design – M. Zielińska

Data collection – M. Zielińska, J. Kucharski

Manuscript preparation – M. Zielińska, J. Kucharski

Literature research – M. Zielińska, J. Kucharski, M. Kotowicz, J. Ciećwierz, A. Zagórska, P. Szajewski, M. Koczkodaj, M. Bieniak, P. Łazicka

Final approval of the version to be published – M. Zielińska, J. Kucharski, M. Kotowicz, J. Ciećwierz, A. Zagórska, P. Szajewski, M. Koczkodaj, M. Bieniak, P. Łazicka



REFERENCES

1. Mak MS, Chowdhury R, Johnson R. Morton's neuroma: review of anatomy, pathomechanism, and imaging. *Clin Radiol*. 2021;76(3):235.e15–235.e23. doi: 10.1016/j.crad.2020.10.006.
2. Bhatia M, Thomson L. Morton's neuroma – Current concepts review. *J Clin Orthop Trauma*. 2020;11(3):406–409. doi: 10.1016/j.jcot.2020.03.024.
3. Wu KK. Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. *J Foot Ankle Surg*. 1996;35(2):112–119; discussion 187–188. doi: 10.1016/s1067-2516(96)80027-5.
4. Morscher E, Ulrich J, Dick W. Morton's intermetatarsal neuroma: morphology and histological substrate. *Foot Ankle Int*. 2000;21(7):558–562. doi: 10.1177/107110070002100705.
5. Bourke G, Owen J, Machet D. Histological comparison of the third interdigital nerve in patients with Morton's metatarsalgia and control patients. *Aust N Z J Surg*. 1994;64(6):421–424. doi: 10.1111/j.1445-2197.1994.tb02243.x.
6. Giakoumis M, Ryan JD, Jani J. Histologic evaluation of intermetatarsal Morton's neuroma. *J Am Podiatr Med Assoc*. 2013;103(3):218–222. doi: 10.7547/1030218.
7. Hassouna H, Singh D. Morton's metatarsalgia: pathogenesis, aetiology and current management. *Acta Orthop Belg*. 2005;71(6):646–655.
8. Santiago FR, Muñoz PT, Pryest P, Martínez AM, Olleta NP. Role of imaging methods in diagnosis and treatment of Morton's neuroma. *World J Radiol*. 2018;10(9):91–99. doi: 10.4329/wjr.v10.i9.91.
9. Latinovic R, Gulliford MC, Hughes RA. Incidence of common compressive neuropathies in primary care. *J Neurol Neurosurg Psychiatry*. 2006;77(2):263–265. doi: 10.1136/jnnp.2005.066696.
10. Hewitt S, Yates B, Williamson D. A prospective audit of referral patterns to a dedicated Foot and Ankle surgical service. *Foot (Edinb)*. 2011;21(4):166–171. doi: 10.1016/j.foot.2011.03.002.
11. Soo MJ, Perera SD, Payne S. The use of ultrasound in diagnosing Morton's neuroma and histological correlation. *Ultrasound*. 2010;18(1):14–17. doi: 10.1258/ult.2009.009006.
12. Valero J, Gallart J, González D, Deus J, Lahoz M. Multiple interdigital neuromas: a retrospective study of 279 feet with 462 neuromas. *J Foot Ankle Surg*. 2015;54(3):320–322. doi: 10.1053/j.jfas.2014.05.011.
13. LiMarzi GM, Scherer KF, Richardson ML, Warden DR 4th, Wasyliv CW, Porrino JA, et al. CT and MR Imaging of the Postoperative Ankle and Foot. *Radiographics*. 2016;36(6):1828–1848. doi: 10.1148/rg.2016160016.
14. Pitcher M, Moulson A, Pitcher D, Herbrand A, Cert G, Cairns MC. Diagnostic Accuracy of Subjective Features and Physical Examination Tests for Morton Neuroma: A Systematic Review. *Foot Ankle Orthop*. 2024;9(4):24730114241291055. doi: 10.1177/24730114241291055.
15. Dando C, Cherry L, Jones L, Bowen C. The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study. *J Foot Ankle Res*. 2017;10:59. doi: 10.1186/s13047-017-0241-2.
16. Mann RA, Reynolds JC. Interdigital neuroma—a critical clinical analysis. *Foot Ankle*. 1983;3(4):238–243. doi: 10.1177/107110078300300411.
17. Bignotti B, Signori A, Sormani MP, Molletta L, Martinoli C, Tagliafico A. Ultrasound versus magnetic resonance imaging for Morton neuroma: systematic review and meta-analysis. *Eur Radiol*. 2015;25(8):2254–2262. doi: 10.1007/s00330-015-3633-3.
18. Xu Z, Duan X, Yu X, Wang H, Dong X, Xiang Z. The accuracy of ultrasonography and magnetic resonance imaging for the diagnosis of Morton's neuroma: a systematic review. *Clin Radiol*. 2015;70(4):351–358. doi: 10.1016/j.crad.2014.10.017.
19. Quinn TJ, Jacobson JA, Craig JG, van Holsbeeck MT. Sonography of Morton's neuromas. *AJR Am J Roentgenol*. 2000;174(6):1723–1728. doi: 10.2214/ajr.174.6.1741723.
20. Sobieski GA, Wertheimer SJ, Schulz R, Dalfovo M. Sonographic evaluation of interdigital neuromas. *J Foot Ankle Surg*. 1997;36(5):364–366. doi: 10.1016/s1067-2516(97)80038-5.
21. Shapiro PP, Shapiro SL. Sonographic evaluation of interdigital neuromas. *Foot Ankle Int*. 1995;16(10):604–606. doi: 10.1177/107110079501601003.
22. Oliver TB, Beggs I. Ultrasound in the assessment of metatarsalgia: a surgical and histological correlation. *Clin Radiol*. 1998;53(4):287–289. doi: 10.1016/s0009-9260(98)80128-1.
23. De Maeseneer M, Madani H, Lenchik L, Kalume Brigido M, Shahabpour M, Marcelis S, et al. Normal Anatomy and Compression Areas of Nerves of the Foot and Ankle: US and MR Imaging with Anatomic Correlation. *Radiographics*. 2015;35(5):1469–1482. doi: 10.1148/rg.2015150028.
24. Torriani M, Kattapuram SV. Technical innovation. Dynamic sonography of the forefoot: The sonographic Mulder sign. *AJR Am J Roentgenol*. 2003;180(4):1121–1123. doi: 10.2214/ajr.180.4.1801121.
25. Bencardino J, Rosenberg ZS, Beltran J, Liu X, Marty-Delfaut E. Morton's neuroma: is it always symptomatic? *AJR Am J Roentgenol*. 2000;175(3):649–653. doi: 10.2214/ajr.175.3.1750649.
26. Zanetti M, Strehle JK, Kundert HP, Zollinger H, Hodler J. Morton neuroma: effect of MR imaging findings on diagnostic thinking and therapeutic decisions. *Radiology*. 1999;213(2):583–588. doi: 10.1148/radiology.213.2.r99nv06583.
27. Saygi B, Yildirim Y, Saygi EK, Kara H, Esemli T. Morton neuroma: comparative results of two conservative methods. *Foot Ankle Int*. 2005;26(7):556–559. doi: 10.1177/107110070502600711.
28. Makki D, Haddad BZ, Mahmood Z, Shahid MS, Pathak S, Garnham I. Efficacy of corticosteroid injection versus size of plantar interdigital neuroma. *Foot Ankle Int*. 2012;33(9):722–726. doi: 10.3113/FAI.2012.0722.
29. Markovic M, Crichton K, Read JW, Lam P, Slater HK. Effectiveness of ultrasound-guided corticosteroid injection in the treatment of Morton's neuroma. *Foot Ankle Int*. 2008;29(5):483–487. doi: 10.3113/FAI.2008-0483.
30. Thomson CE, Beggs I, Martin DJ, McMillan D, Edwards RT, Russell D, et al. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. *J Bone Joint Surg Am*. 2013;95(9):790–798. S1. doi: 10.2106/JBJS.1.01780.
31. Mahadevan D, Attwal M, Bhatt R, Bhatia M. Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. *Bone Joint J*. 2016;98-B(4):498–503. doi: 10.1302/0301-620X.98B4.36880.
32. Musson RE, Sawhney JS, Lamb L, Wilkinson A, Obaid H. Ultrasound guided alcohol ablation of Morton's neuroma. *Foot Ankle Int*. 2012;33(3):196–201. doi: 10.3113/FAI.2012.0196.
33. Gurdezi S, White T, Ramesh P. Alcohol injection for Morton's neuroma: a five-year follow-up. *Foot Ankle Int*. 2013;34(8):1064–1067. doi: 10.1177/1071100713489555.
34. Hyer CF, Mehl LR, Block AJ, Vancourt RB. Treatment of recalcitrant intermetatarsal neuroma with 4% sclerosing alcohol injection: a pilot study. *J Foot Ankle Surg*. 2005;44(4):287–291. doi: 10.1053/j.jfas.2005.04.010.
35. Dockery GL. The treatment of intermetatarsal neuromas with 4% alcohol sclerosing injections. *J Foot Ankle Surg*. 1999;38(6):403–408. doi: 10.1016/s1067-2516(99)80040-4.
36. Fanucci E, Masala S, Fabiano S, Perugia D, Squillaci E, Varrucchi V, et al. Treatment of intermetatarsal Morton's neuroma with alcohol injection under US guide: 10-month follow-up. *Eur Radiol*. 2004;14(3):514–518. doi: 10.1007/s00330-003-2057-7.
37. Pasquali C, Vulcano E, Novario R, Varotto D, Montoli C, Volpe A. Ultrasound-guided alcohol injection for Morton's neuroma. *Foot Ankle Int*. 2015;36(1):55–59. doi: 10.1177/1071100714551386.
38. Hughes RJ, Ali K, Jones H, Kendall S, Connell DA. Treatment of Morton's neuroma with alcohol injection under sonographic guidance: follow-up of 101 cases. *AJR Am J Roentgenol*. 2007;188(6):1535–1539. doi: 10.2214/AJR.06.1463.
39. Deniz S, Purtuloglu T, Tekindur S, Cansız KH, Yetim M, Kılıçkaya O, et al. Ultrasound-guided pulsed radio frequency treatment in Morton's neuroma. *J Am Podiatr Med Assoc*. 2015;105(4):302–306. doi: 10.7547/13-128.1.
40. Chuter GS, Chua YP, Connell DA, Blackney MC. Ultrasound-guided radiofrequency ablation in the management of interdigital (Morton's) neuroma. *Skeletal Radiol*. 2013;42(1):107–111. doi: 10.1007/s00256-012-1527-x.
41. Caporusso EF, Fallat LM, Savoy-Moore R. Cryogenic neuroablation for the treatment of lower extremity neuromas. *J Foot Ankle Surg*. 2002;41(5):286–290. doi: 10.1016/s1067-2516(02)80046-1.
42. Seok H, Kim SH, Lee SY, Park SW. Extracorporeal Shockwave Therapy in Patients with Morton's Neuroma A Randomized, Placebo-Controlled Trial. *J Am Podiatr Med Assoc*. 2016;106(2):93–99. doi: 10.7547/14-131.
43. Fridman R, Cain JD, Weil L Jr. Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial. *J Am Podiatr Med Assoc*. 2009;99(3):191–193. doi: 10.7547/0980191.
44. Campbell CM, Diamond E, Schmidt WK, Kelly M, Allen R, Houghton W, et al. A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton's neuroma. *Pain*. 2016;157(6):1297–1304. doi: 10.1097/j.pain.0000000000000544.
45. Climent JM, Mondéjar-Gómez F, Rodríguez-Ruiz C, Díaz-Llopis I, Gómez-Gallego D, Martín-Medina P. Treatment of Morton neuroma with botulinum toxin A: a pilot study. *Clin Drug Investig*. 2013;33(7):497–503. doi: 10.1007/s40261-013-0090-0.
46. Kilmartin TE, Wallace WA. Effect of pronation and supination orthosis on Morton's neuroma and lower extremity function. *Foot Ankle Int*. 1994;15(5):256–262. doi: 10.1177/107110079401500505.
47. Gimber LH, Melville DM, Bocian DA, Krupinski EA, Guidice MP, Taljanovic MS. Ultrasound Evaluation of Morton Neuroma Before and After Laser Therapy. *AJR Am J Roentgenol*. 2017;208(2):380–385. doi: 10.2214/AJR.16.16403.
48. Thomson L, Aujla RS, Divall P, Bhatia M. Non-surgical treatments for Morton's neuroma: A systematic review. *Foot Ankle Surg*. 2020;26(7):736–743. doi: 10.1016/j.fas.2019.09.009.
49. Matthews BG, Thomson CE, Harding MP, McKinley JC, Ware RS. Treatments for Morton's neuroma. *Cochrane Database Syst Rev*. 2024;2(2):CD014687. doi: 10.1002/14651858.CD014687.pub2.
50. Lee K, Hwang IY, Ryu CH, Lee JW, Kang SW. Ultrasound-Guided Hyaluronic Acid Injection for the Management of Morton's Neuroma. *Foot Ankle Int*. 2018;39(2):201–204. doi: 10.1177/1071100717739578.



51. Choi JY, Hong WH, Kim MJ, Chae SW, Suh JS. Operative treatment options for Morton's neuroma other than neurectomy – a systematic review. *Foot Ankle Surg.* 2022;28(4):450–459. doi: 10.1016/j.fas.2021.10.011.
52. Elghazy MA, Whitelaw KC, Waryasz GR, Guss D, Johnson AH, DiGiovanni CW. Isolated Intermetatarsal Ligament Release as Primary Operative Management for Morton's Neuroma: Short-term Results. *Foot Ankle Spec.* 2022;15(4):338–345. doi: 10.1177/1938640020957851.
53. Mischitz M, Zeitlinger S, Mischlinger J, Rab M. Nerve decompression according to A.L. Dellon in Morton's neuroma – A retrospective analysis. *J Plast Reconstr Aesthet Surg.* 2020;73(6):1099–1104. doi: 10.1016/j.bjps.2020.01.008.
54. Koti M, Maffulli N, Al-Shoaibi M, Hughes M, McAllister J. Long-term results of dorsal neuroma/nerve transposition in the surgical management of Morton's neuroma and correlation with intraoperative anatomical variations. *J Orthop Surg Res.* 2022;17(1):22. doi: 10.1186/s13018-022-02910-2.